Tumor-associated tissue via lipiodol-mediated deposition

Tumor-associated tissue via lipiodol-mediated deposition refers to the selective accumulation of ethiodized oil within hypervascular tumors, most notably hepatocellular carcinoma (HCC). This phenomenon is not a specific molecular target like a receptor or enzyme, but rather a physiological targeting mechanism based on the abnormal vascular architecture of tumors (Gaba RC, et al., Journal of Vascular and Interventional Radiology, 2016). Lipiodol serves a dual purpose as a contrast medium for imaging and a delivery vehicle for lipophilic or emulsified chemotherapeutic agents. During transarterial chemoembolization (TACE), the oil-drug mixture is injected into the hepatic artery, where it preferentially lodges in the tumor interstitium due to the enhanced permeability and retention (EPR) effect. This localization allows for the delivery of high-dose chemotherapy directly to the lesion while minimizing systemic toxicity. The sustained presence of the oil also contributes to tumor ischemia by physically blocking the microvasculature. Consequently, this 'target' represents a localized anatomical site for therapeutic intervention rather than a biochemical molecule.

Other names

Lipiodol-targeted tumor tissueEthiodized oil deposition siteTACE-targeted tumor microenvironmentLipiodol-retaining tumor stroma

Lipiodol acts as a radio-opaque vehicle that selectively carries and retains chemotherapeutic agents within tumor tissue. The mechanism relies on the unique vascularity of tumors, specifically the 'leaky' endothelium and the absence of Kupffer cells and functional lymphatic drainage, which prevents the clearance of the oil-drug emulsion (Idée JM, et al., Critical Reviews in Oncology/Hematology, 2006). This results in high local drug concentrations and prolonged exposure, often followed by the embolic occlusion of feeding vessels to induce ischemic necrosis (Lencioni R., Seminars in Liver Disease, 2011).